cyclothiazide

Also known as Anhydron®, Aquirel®, 6-chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide, 6-chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide, 6-chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide, 6-chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide, 6-chloro-3,4-dihydro-3-(2-Norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide, Cyclothiazidum

Cyclothiazide (Anhydron, Acquirel, Doburil, Fluidil, Renazide, Tensodiural, Valmiran), sometimes abbreviated CTZ, is a benzothiadiazide (thiazide) diuretic and antihypertensive that was originally introduced in the United States in 1963 by Eli Lilly and was subsequently also marketed in Europe and Japan. Related drugs include diazoxide, hydrochlorothiazide, and chlorothiazide.

Research

592 papers

[CYCLOTHIAZIDE].Meditsinskaia promyshlennost' SSSR · 1964
Allosteric competition and inhibition in AMPA receptors.Nature structural & molecular biology · 2024
Cyclothiazide prolongs low [Mg2+]-induced seizure-like events.Journal of neurophysiology · 2006
Cyclothiazide differentially modulates desensitization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor splice variants.Molecular pharmacology · 1994
Cyclothiazide: a subunit-specific inhibitor of GABAC receptors.The Journal of physiology · 2008

via PubMed

Wikidata facts

Mass: 389.027076

Show 5 more facts

chemical formula: C₁₄H₁₆ClN₃O₄S₂
defined daily dose: 5.0
canonical SMILES: C1C2CC(C1C=C2)C3NC4=CC(=C(C=C4S(=O)(=O)N3)S(=O)(=O)N)Cl
World Health Organisation international non-proprietary name: cyclothiazide
Commons category: Cyclothiazide

Sources (3)

via Wikidata · CC0

~2 min read

Article

3 sections

Contents

Synthesis
See also
References

In 1993, it was discovered that cyclothiazide is a positive allosteric modulator of the AMPA and kainate receptors, capable of reducing or essentially eliminating rapid desensitization of the former receptor, and potentiating AMPA-mediated glutamate currents by as much as 18-fold at the highest concentration tested (100 μM). Additionally, in 2003, cyclothiazide was also found to act as a GABAA receptor negative allosteric modulator, potently inhibiting GABAA-mediated currents. In animals it is a powerful convulsant, robustly enhancing epileptiform activity and inducing seizures, but without producing any apparent neuronal death.